Horizon Pharma triples size of U.S. headquarters; U.K. regulators join hands with Indian agency;

@FiercePharma: ICYMI: Merck's Keytruda gets FDA approval for NSCLC ahead of BMS' Opdivo but label is limited. Article | Follow @FiercePharma

@EricPFierce: Swiss CMO Seigfried completes $302M deal for BASF API plants. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Ackman's fund takes a beating on Valeant pricing worries. Item | Follow @CarlyHFierce

> Though Horizon Pharma ($HZNP) is technically based in Ireland, its U.S. headquarters is where the action is, and the company is tripling the size of that operation with a move to Lake Forest, IL, from nearby Deerfield. Report

> The U.K.'s Medicines and Healthcare Regulatory Agency is joining forces with its Indian counterpart in a pact to collaborate on overseeing the drug and device business in their respective countries. Report

> India's Biocon saw its shares rise by 2% after announcing it would buy a manufacturing unit from another Indian company, Acacia Life Sciences. Report

> Pfizer ($PFE) wrapped up its $130 million buyout of two GlaxoSmithKline ($GSK) meningococcal vaccines, Nimenrix and Mencevax. Report

> Indivior plans to sue Novartis' ($NVS) generics unit Sandoz for patent infringement after the latter filed for FDA approval for a copycat version of suboxone sublingual film. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Investigational spinal cord implant bringing bodily sensation back to the lives of the paralyzed. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: FTC weighs in on Mylan case, saying generics tweaking may be anticompetitive. Story | Follow @EmilyWFierce

> Boston Scientific wins $200M stent patent infringement case against doctor. Report

> Europe grants its first CE mark for leadless pacemaker to treat left ventricle. Article

Biotech News

@FierceBiotech: Spark soars on success of gene therapy study, shot at groundbreaking approval. Report | Follow @FierceBiotech

@JohnCFierce: That Shkreli scandal? Infecting Valeant and Mike Pearson as the industry runs away as fast as possible. New York Times article | Follow @JohnCFierce

> Trans-Pacific trade pact compromises on drug exclusivity with 5- to 8-year haven. Story

> Baxalta and Momenta target Humira with a Phase III biosimilar trial. Article

Animal Health News

> International health groups vow renewed effort to eradicate rabies. Report

> FDA seeks veterinarians' input on antibiotics resistance. Item

> USDA: Deadly pig virus likely carried into U.S. from China. More

> Stem cell treatment proves promising in dogs with Crohn's-like disease. Article

> WHO chief Margaret Chan vows to boost preparedness for disease outbreaks. Story

Biotech IT News

> Mount Sinai, Yale roll out updates to Apple ResearchKit programs. Report

> Allergan taps NuMedii's digital discovery platform for psoriasis R&D. News

> Illumina readies paid-for BaseSpace tiers for large organizations. More

> Cloud Pharmaceuticals, Therametrics hook up for CNS drug discovery drive. Story

> Berg to apply AI drug discovery model to U.K.'s genome data repository. Article

Pharma Marketing News

> BioMarin eyes SG&A efficiency on Kuvan; no worries on rare-disease pricing. Item

> Want to get a warning letter from OPDP? Omit drug risks from your promos. Story

> Teva snaps up Gecko and its 'smart inhaler' to pump up respiratory meds. More

> Veeva scoops up rival Zinc Ahead to create mega-content management platform. Report

> Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. Article

And Finally... A Chinese biotech company says it has solved a vexing problem: Keeping pigs to housepet size. Report

Suggested Articles

If Pfizer wants Lorbrena to be a true follow-up to Xalkori, it has to win a first-line OK in ALK-positive lung cancer. And it just got closer.

Eylea sales dropped 4% to $1.11 billion amid the pandemic, but still beat expectations. And meanwhile, Regeneron's COVID antibody is advancing.

Johnson & Johnson inked a $10-per-dose vaccine supply deal with the U.S. for 100 million initial doses, with 200 million more available down the line.